Loading clinical trials...
Loading clinical trials...
Phase I Dose Escalation and Preliminary Efficacy Study of Bispecific CD19 and CD22 Chimeric Antigen Receptor Co-Expressing T Cells (CD19x22 CAR T) in Pediatric Patients With Relapsed and/or Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Conditions
Interventions
CD19x22 CAR T
Locations
1
United States
Children's Hospital Colorado
Aurora, Colorado, United States
Start Date
September 27, 2024
Primary Completion Date
December 1, 2028
Completion Date
December 1, 2029
Last Updated
November 28, 2025
NCT07523555
NCT06395103
NCT07223021
NCT05674175
NCT07429461
NCT06785818
Lead Sponsor
University of Colorado, Denver
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions